Henan Grand Biowin Pharmaceutical

Henan Grand Biowin Pharmaceutical is a China-based biotechnology company focused on the research and development of innovative therapies for metabolic diseases, including obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). As a subsidiary of Grand Pharmaceutical Group, the company leverages advanced drug discovery platforms to develop multi-target agonists and long-acting biologics. Their pipeline features several high-potential candidates, such as GLP-1/GIP/GCGR triple agonists and FGF21 analogs, aimed at addressing significant unmet needs in the global metabolic health market. The company operates integrated R&D and manufacturing facilities to support its transition from early-stage research to clinical development and commercialization.